Autoantibodies against nucleosomes are considered a hallmark of systemic lupus erythematosus (SLE). We compared in patients with proliferative lupus nephritis the diagnostic usefulness of a dsDNA-loaded nucleosome ELISA (anti-dsDNA-NcX) with ELISAs in which dsDNA or nucleosomes alone were coated. First, we analysed whether DNA loading on nucleosomes led to masking of epitopes by using defined monoclonal anti-DNA, anti-histone and nucleosome-specific autoantibodies to evaluate the accessibility of nucleosomal epitopes in the anti-dsDNA-NcX ELISA. Second, autoantibody levels were measured in these 3 ELISAs in 100 patients with proliferative lupus nephritis (LN) before immunosuppressive treatment and in 128 non-SLE disease controls. In patients with LN inter-assay comparisons and associations with clinical and serological parameters were analysed. The panel of monoclonal antibodies revealed that all epitopes were equally accessible in the anti-dsDNA-NcX ELISA as in the two other ELISAs. Patients with proliferative lupus nephritis were positive with dsDNA-loaded nucleosomes in 86%, with DNA in 66% and with nucleosomes in 85%. In the non-lupus disease control group these frequencies were 1.6% (2 out of 128) for both the anti-dsDNA-NcX and the anti-dsDNA ELISA and 0% in the anti-nucleosome ELISA. The levels in the anti-dsDNA-NcX ELISA were high in a group of patients with LN that showed absent reactivity in the anti-DNA or low levels in the anti-nucleosome ELISA. Anti-dsDNA-NcX positivity was associated with higher SLEDAI scores within this group. Within nucleosome-based ELISAs, we propose the anti-dsDNA-NcX ELISA as the preferred test system.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.molimm.2015.06.004DOI Listing

Publication Analysis

Top Keywords

patients proliferative
16
proliferative lupus
16
lupus nephritis
16
anti-dsdna-ncx elisa
16
elisa
8
elisa anti-dsdna-ncx
8
anti-nucleosome elisa
8
anti-dsdna-ncx
7
nucleosomes
6
patients
6

Similar Publications

Purpose: To provide insights into the transscleral removal technique for subretinal proliferative tissues (SRP).

Study Design: Retrospective, single-center case series.

Methods: Patients who underwent transscleral removal of SRP during vitrectomy for rhegmatogenous retinal detachment (RRD) were included.

View Article and Find Full Text PDF

Identification of an immunological signature of long COVID syndrome.

Front Immunol

January 2025

Neuroimmunology Unit, Santa Lucia Foundation IRCCS, Rome, Italy.

Introduction: Acute COVID-19 infection causes significant alterations in the innate and adaptive immune systems. While most individuals recover naturally, some develop long COVID (LC) syndrome, marked by persistent or new symptoms weeks to months after SARS-CoV-2 infection. Despite its prevalence, there are no clinical tests to distinguish LC patients from those fully recovered.

View Article and Find Full Text PDF

Downregulation of MerTK in circulating T cells of patients with non-proliferative diabetic retinopathy.

Front Endocrinol (Lausanne)

January 2025

Department of Ophthalmology, The Second Affiliated Hospital, School of Medicine, South China University of Technology, Guangzhou, China.

Objective: To explore the differential gene expression in peripheral blood immune cells of individuals with type 2 diabetes mellitus (DM), comparing those with and without non-proliferative diabetic retinopathy (NPDR).

Methods: From a pool of 126 potential participants, 60 were selected for detailed analysis. This group included 12 healthy donors (HDs), 22 individuals with DM, and 26 with NPDR.

View Article and Find Full Text PDF

Introduction: and research question: Prognostic factors to predict the behavior of pituitary neuroendocrine tumors (PitNET) are scarce. PD-L1 expression was associated with prognosis in other neuroendocrine neoplasms and we analyzed PD-L1 expression in PitNET, according to the 2022 WHO classification.

Material And Methods: A retrospective analysis was performed.

View Article and Find Full Text PDF

[Short-term efficacy of rituximab in children with calcineurin inhibitor resistant steroid resistant nephrotic syndrome].

Zhonghua Er Ke Za Zhi

January 2025

Department of Nephrology, Children's Hospital of Fudan University, National Children's Medical Center, Shanghai Kidney Development and Pediatric Kidney Disease Research Center State, Key Laboratory of Kidney Diseases, Shanghai201102, China.

To investigate the short-term efficacy and safety of rituximab (RTX) in children with calcineurin inhibitor (CNI) resistant steroid resistant nephrotic syndrome (SRNS). A retrospective case analysis was conducted. Thirteen children with CNI resistant SRNS who were regularly treated with RTX (375 mg/m per dose (maximum dose 500 mg), 1 dose per week, a total of 4 doses) in Department of Nephrology, Children's Hospital of Fudan University from January 2016 to December 2023 were enrolled.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!